Sucralfate for Radiation Esophagitis

Phase-Based Progress Estimates
Radiation EsophagitisSucralfate - Drug
All Sexes
What conditions do you have?

Study Summary

The purpose of the study is to explore options for preventing and reducing symptoms of radiation esophagitis (RE). The researchers will also look what symptoms participants experience, and whether there are differences in weight loss in participants.

Eligible Conditions
  • Radiation Esophagitis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 2 years

1 year
Accrual rate (Two-stage consent part)
2 years
Reduce opioid use

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

4 Treatment Groups

Usual Care
1 of 4
One Stage Consent
1 of 4
1 of 4
Two Stage Consent
1 of 4

Active Control

Experimental Treatment

352 Total Participants · 4 Treatment Groups

Primary Treatment: Sucralfate · No Placebo Group · Phase 2

Experimental Group · 1 Intervention: Sucralfate · Intervention Types: Drug
Two Stage Consent
Experimental Group · 1 Intervention: Two consent · Intervention Types: Other
Usual Care
ActiveComparator Group · 1 Intervention: Usual Care · Intervention Types: Other
One Stage Consent
ActiveComparator Group · 1 Intervention: One consent · Intervention Types: Other
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,832 Previous Clinical Trials
584,065 Total Patients Enrolled
Jacob Shin, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have received at least 15% (10-14 fractions) of the prescribed dose.
You are at least 18 years old.
You have received at least 15% of the prescribed dose (25-35 fractions) for radiotherapy.
You have received at least 15-24 radiation fractions with a V40 ≥ 15%.